Siemens Healthineers, Biogen Release: Companies Announce Agreement To Jointly Develop New MRI Tools For Multiple Sclerosis

• Project will explore quantitative MRI metrics for more informed treatment decision making

ERLANGEN, Germany & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Siemens Healthineers and Biogen have announced that the companies plan to jointly develop magnetic resonance imaging (MRI) applications with the intent of quantifying key markers of multiple sclerosis (MS) disease activity and progression. Biogen is a leading biotechnology company with a deep focus on neurological and autoimmune conditions, which for two decades has been at the forefront of delivering therapies to MS patients. Siemens Healthineers aims to enable healthcare providers to meet their current challenges and excel in their respective environments. To execute this strategy in the field of neurology, Siemens Healthineers will cooperate with Biogen and contributes its strength in medical imaging.

“By bringing together the shared expertise of both Siemens Healthineers and Biogen in imaging and neurology, respectively, we seek to develop new measurement tools that meet the particular technical challenges of MS”

“By bringing together the shared expertise of both Siemens Healthineers and Biogen in imaging and neurology, respectively, we seek to develop new measurement tools that meet the particular technical challenges of MS,” said Dr. Christoph Zindel, Senior Vice President of Magnetic Resonance Imaging at Siemens Healthineers. “Our shared goal is to create a solution that can be integrated into the existing radiology workflow, so it can become a seamless part of routine care – delivering new and valuable information to treating neurologists without increasing the cost or burden on the healthcare system.”

MRI is routinely used to support physicians in diagnosing MS, measuring disease activity and monitoring response to therapy. Clinicians qualitatively evaluate MRIs by comparing the current MRI to the previous MRI. Numerous studies have demonstrated that quantitative MRI measures may provide additional information about disease prognosis and therapeutic effect, but today quantitative measurement techniques with the precision and sensitivity required for MS are typically only available in the research setting. With the development and validation of automated MRI applications to quantify key markers of MS, including new T2 lesions and brain atrophy, patients could benefit from the availability of enhanced data at the point of care.

“Biogen believes that the availability of high-quality, standardized data at the point of care can lead to a deeper understanding of MS, more informed treatment decisions and, ultimately, improved patient outcomes,” said Richard Rudick, MD, Vice President Development Sciences, Biogen. “We also recognize that the ability to generate research-quality data in the course of routine clinical practice can unlock the potential of the health care system to move towards precision medicine.”

The products/features (here mentioned) are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Further details are available from the local Siemens organizations.

Siemens Healthineers is the separately managed healthcare business of Siemens AG enabling healthcare providers worldwide to meet their current challenges and to excel in their respective environments. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. To help customers succeed in today’s dynamic healthcare marketplace, Siemens Healthineers is championing new business models that maximize opportunity and minimize risk for healthcare providers. In fiscal 2016, which ended on September 30, 2016, Siemens Healthineers generated revenue of €13.5 billion and net income of over €2.3 billion and has about 46,000 employees worldwide. Further information is available at www.siemens.com/healthineers.

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, please visit www.biogen.com. Follow us on Twitter.